Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

ASCO GU 2020: Dr. Sonpavde Highlights Advancements in Bladder Cancer

February 14th 2020

ASCO GU 2020: Dr. Galsky Provides Insight on Potentially Practice-Changing Studies in Bladder Cancer

February 14th 2020

ASCO GU 2020: Dr. Albiges Recounts Exciting Research in RCC

February 14th 2020

OncLive News Network On Location: GU 2020 Day 3

February 14th 2020

OncLive News Network On Location: GU 2020 Day 2

February 14th 2020

OncLive News Network On Location: GU 2020 Day 1

February 14th 2020

Dr. Pal on Cohort Findings of COSMIC-021 Trial in mCRPC

February 14th 2020

Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.

Dr. Cheng on the Goals of the GENTleMEN Trial in Prostate Cancer

February 14th 2020

Heather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.

3 Keys to Prostate Cancer Care: Clarify, Classify, Personalize

February 12th 2020

The treatment paradigm for patients with prostate cancer is evolving, with the growth of approved and newly developed agents and an increased understanding of the role of genomic drivers.

Dr. Agarwal on Drug Development in Metastatic Castration-Sensitive Prostate Cancer

February 12th 2020

Neeraj Agarwal, MD, discusses the need for further drug development in metastatic castration-sensitive prostate cancer.

Enzalutamide Improves Survival in Nonmetastatic CRPC

February 12th 2020

Enzalutamide plus androgen deprivation therapy demonstrated a statistically significant improvement in overall survival compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Oh on Targeted Treatment in Metastatic Castration-Resistant Prostate Cancer

February 8th 2020

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, and deputy director of The Tisch Cancer Institute, discusses targeted treatment in metastatic castration-resistant prostate cancer (mCRPC).

New Treatment Indications Boost Survival in Metastatic Hormone-Sensitive Prostate Cancer

February 7th 2020

William K. Oh, MD, sheds light on how he approaches treatment in patients with metastatic hormone-sensitive prostate cancer.

Dr. Hwang on the Evolution of Treatment in Metastatic CSPC

February 7th 2020

Clara Hwang, MD, discusses the evolution of treatment for men with metastatic castration-sensitive prostate cancer.

Dr. Sartor on Emerging Agents in Prostate Cancer

February 6th 2020

A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses emerging agents in prostate cancer.

Education, Collaboration Key to Increasing Genetic Screening in Prostate Cancer

February 5th 2020

Thomas J. Polascik, MD, discusses the growing relevance of genetic testing for men with prostate cancer and those at a high risk of developing the disease.

Dr. Morris on Treatment Considerations for CRPC

February 5th 2020

David Morris, MD, FACS, discusses choosing the best agent to treat patients with nonmetastatic castration-resistant prostate cancer.

Dr. Chang on Adjuvant Versus Salvage Radiation in High-Risk Prostate Cancer

February 4th 2020

Sam S. Chang, MD, MBA, discusses adjuvant versus salvage radiation in patients with nonmetastatic high-risk prostate cancer.

Darolutamide Nears EU Approval for Nonmetastatic CRPC

February 1st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease.

Darolutamide Improves Survival in Nonmetastatic CRPC

January 30th 2020

Darolutamide plus androgen deprivation therapy (ADT) led to a significant improvement in overall survival (OS) compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer, according to results from a preplanned final OS analysis of the phase III ARAMIS trial.